The Leadership
Our Founder
​
Cameron Durrant, MD, DRCOG, MRCGP, MBA, FLSW, has spent a lifetime as a physician and as a leader in the development of medicines. As our founder, he brings to Taran experience as a pharma/biotech entrepreneur, operating executive and board member, and as a long-time Chief Executive Officer. Dr. Durrant was Chairman of the Board and CEO of Humanigen for eight years before acquiring that company’s assets for Taran early in 2024. Dr. Durrant served on the boards of several public and privately-held healthcare companies. He has been a senior executive at Johnson and Johnson, Pharmacia, GSK and Merck. Dr. Durrant earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, his DipCH from the Melbourne Academy, Australia, and his MBA from Henley Management College, Oxford, UK.
Cameron Durrant, MD, DRCOG, MRCGP, MBA, FLSW
Board and Advisors
​
Michael Schuster Co-Founded Mesoblast Limited and Angioblast Systems Inc. in 2004. He was part of the executive management team at both companies and currently serves as the head of pharma partnering and project management at Mesoblast Limited and was previously the head of the company's investor relations outreach program. Mr Schuster was Executive Vice President of Global Therapeutic Programs from 2010 to 2013 and was the Director of Business Development and Vice President of Operations from 2004 to 2010. He holds an undergraduate degree in science from Tufts University, a Master's degree in Immunology & Microbiology from New York Medical College, and an MBA from Fordham University in New York.
Michael Schuster
Michael North is an experienced corporate executive with international experience, working with investors to tailor anticipated results to available resources. He provides communications with prospective investors and key stakeholders in Taran Therapeutics. Michael works directly with the chief executives of the company, helping to formulate its mission, vision, and long-term investment strategy. He has a long commitment to the life sciences, specifically to making fundamental therapies that penetrate to root causes widely available.
